Pzena Investment Management LLC Trims Stock Holdings in Fresenius Medical Care AG & Co. KGaA $FMS

Pzena Investment Management LLC lowered its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 0.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 14,752,836 shares of the company’s stock after selling 64,016 shares during the period. Fresenius Medical Care AG & Co. KGaA comprises about 1.1% of Pzena Investment Management LLC’s portfolio, making the stock its 27th largest holding. Pzena Investment Management LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $351,413,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. CIBC Private Wealth Group LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after buying an additional 1,103 shares during the last quarter. Group One Trading LLC purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 3rd quarter valued at about $74,000. EverSource Wealth Advisors LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 141.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,906 shares of the company’s stock valued at $83,000 after buying an additional 1,704 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 3rd quarter valued at about $120,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 21.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock valued at $146,000 after buying an additional 896 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Price Performance

NYSE:FMS opened at $22.51 on Friday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.02 and a 52 week high of $29.71. The company has a quick ratio of 0.86, a current ratio of 1.20 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $12.57 billion, a PE ratio of 11.85, a price-to-earnings-growth ratio of 4.01 and a beta of 0.81. The stock’s 50-day moving average price is $22.44 and its 200-day moving average price is $23.08.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Tuesday, March 31st. The company reported $1.05 EPS for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The firm had revenue of $5.34 billion for the quarter. As a group, equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Monday, June 8th. Stockholders of record on Friday, May 22nd will be given a dividend of $0.8716 per share. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. The ex-dividend date is Friday, May 22nd. This represents a dividend yield of 387.0%. Fresenius Medical Care AG & Co. KGaA’s payout ratio is 30.00%.

Wall Street Analysts Forecast Growth

FMS has been the subject of a number of recent research reports. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, April 24th. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings lowered Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Erste Group Bank lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, May 6th. Five equities research analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $28.00.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.